HERON THERAPEUTICS, INC. /DE/ financials

HRTX CIK 0000818033

Source: EDGAR filings · Built 2026-06-02T03:14:38Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -27.91M -24.23M -60.33M -148.74M -206.38M -191.63M
EBITDA -224.00K -9.04M -107.72M -171.77M -214.81M -225.32M
Working Capital 141.97M 117.56M 109.09M 123.08M 183.37M 211.69M
Net Debt 4.09M 126.94M 126.69M 142.11M 68.95M -87.58M
Gross Margin 73.31% 73.21% 48.75% 49.04% 46.70% 12.65%
Operating Margin -1.64% -7.99% -87.07% -162.21% -252.27% -257.41%
Net Margin -13.04% -9.41% -87.02% -169.05% -255.58% -256.41%
Return on Equity (ROE) -140.90% 40.36% 325.43% -1341.17% -284.50% -96.10%
Return on Assets (ROA) -7.89% -5.82% -49.69% -72.53% -72.19% -64.28%
Current Ratio 2.48× 2.29× 2.37× 2.49× 3.58× 3.07×
Debt-to-Equity 2.28× -4.54× -4.57× 11.60× 2.06× 0.07×
Cash Conversion Ratio 1.37× 1.66× 0.53× 0.81× 0.92× 0.81×
Accruals Ratio 0.03× 0.04× -0.23× -0.14× -0.06× -0.12×
SBC % of Revenue 6.67% 8.98% 25.86% 39.92% 54.26% 56.66%
CapEx Coverage -87.04× -13.21× -38.05× -80.50× -67.29× -27.13×
Free Cash Flow Per Share $-0.17 $-0.16 $-0.44 $-1.37 $-2.10 $-2.11

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 1.58× 1.61× 2.01× 2.77× 10.79× 21.81×
P/B 18.43× 21.95× 12.01× 8.17×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cost of Goods and Services Sold 41.35M 38.65M 65.11M 54.87M 46.02M 36.19M
Gross Profit 113.56M 105.64M 61.94M 52.80M 11.21M
Research and Development Expense 12.43M 16.68M 39.13M 82.70M 130.82M 174.53M
Operating Income (Loss) -2.54M -11.53M -110.61M -174.66M -217.83M -228.16M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -20.20M -13.58M -110.56M -182.02M -220.68M -227.28M
Earnings Per Share, Basic $-0.12 $-0.09 $-0.80 $-1.67 $-2.24
Weighted Average Number of Shares Outstanding, Basic 166.71M 152.45M 138.13M 108.88M 98.47M
Earnings Per Share, Diluted $-0.12 $-0.09 $-0.80 $-1.67 $-2.24
Weighted Average Number of Shares Outstanding, Diluted 166.71M 152.45M 138.13M 108.88M 98.47M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 28.65M 25.80M 28.68M 15.36M 90.54M 105.14M
Assets, Current 238.07M 209.01M 188.77M 205.44M 254.42M 314.20M
Assets 255.88M 233.15M 222.51M 250.95M 305.71M 353.56M
Liabilities, Current 96.10M 91.46M 79.69M 82.36M 71.06M 102.50M
Liabilities 241.54M 266.80M 256.48M 237.38M 228.14M 117.06M
Stockholders' Equity Attributable to Parent 14.33M -33.65M -33.97M 13.57M 77.57M 236.49M
Common Stock, Shares, Outstanding 188.31M 152.13M 150.29M 119.15M 102.00M 91.31M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -27.59M -22.53M -58.79M -146.91M -203.35M -184.82M
Payments to Acquire Property, Plant, and Equipment 317.00K 1.71M 1.54M 1.82M 3.02M 6.81M
Net Cash Provided by (Used in) Investing Activities 16.01M 18.71M 18.00M -3.32M 32.73M 208.96M
Net Cash Provided by (Used in) Financing Activities 14.43M 940.00K 54.11M 75.06M 156.03M 9.11M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (HRTX CIK 0000818033), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ATRC

AtriCure, Inc.

HLIT

HARMONIC INC.

REXR

Rexford Industrial Realty, Inc.